Amylyx begins dosing in Phase II trial of AMX0035 for ALS

Amylyx Pharmaceuticals has begun dosing patients in the Phase II CENTAUR clinical trial of its therapeutic candidate, AMX0035, to treat those with amyotrophic lateral sclerosis (ALS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: Available online 23 June 2018 Source:Neuroscience Research Author(s): Takenari Yamashita, Shin Kwak TAR DNA-binding protein (TDP-43) pathology in the motor neurons is the most reliable pathological hallmark of amyotrophic lateral sclerosis (ALS), and motor neurons bearing TDP-43 pathology invariably exhibit failure in RNA editing at the GluA2 glutamine/arginine (Q/R) site due to down-regulation of adenosine deaminase acting on RNA 2 (ADAR2). Conditional ADAR2 knockout (AR2) mice display ALS-like phenotype, including progressive motor dysfunction due to loss of motor neurons. Motor neurons devoid of ADAR2...
Source: Neuroscience Research - Category: Neuroscience Source Type: research
Inclusion Body Myopathy (IBM) associated with Paget's disease of the bone (PDB) and/or frontotemporal dementia (FTD) or Multisystem Proteinopathy (OMIM 167320) or more commonly called IBMPFD or VCP disease, was first reported by Kimonis et al. (2000) [1]. VCP disease comprises other less common phenotypes including amyotrophic lateral sclerosis (ALS), Parkinson's disease, cardiomyopathy, sensory motor axonal neuropathy, and sphincter disturbance [2 –6]. IBMPFD is an underdiagnosed disease that has been reported in greater than 100 families worldwide, but is more commonly found in the United States and Europe.
Source: Neuromuscular Disorders - Category: Neurology Authors: Source Type: research
Many thanks for forwarding the letter from T. Kawada [1] addressing our manuscript on the lack of association between ADHD and ALS in this journal [2]. In principle, the author points out that this topic would deserve further epidemiological studies to come to a more substantiated conclusion. Pathophysiological considerations alone would not suffice to exclude a causal relationship between these two neurodevelopmental and neurodegenerative, respectively, conditions.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research
Adding rasagiline to riluzole did not extend survival, the primary endpoint, in amyotrophic lateral sclerosis, but post hoc analysis suggests it may benefit those deemed'fast progressors. 'Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
(University of California - Riverside) Maurizio Pellecchia at the University of California, Riverside has received two grants to continue his research aimed at finding therapeutics for cancer, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. The first grant from the US-Egypt Science and Technology Joint Fund of the National Academy of Sciences, Engineering, and Medicine totals $190,000 for two years. The second is a nearly $2.3 million, five-year grant from the National Institute of Neurological Disorders and Stroke.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Publication date: Available online 20 June 2018 Source:Molecular Immunology Author(s): Anne-Lene Kjældgaard, Katrine Pilely, Karsten Skovgaard Olsen, Stephen Wørlich Pedersen, Anne Øberg Lauritsen, Kirsten Møller, Peter Garred Amyotrophic lateral sclerosis (ALS) is a devastating, neurodegenerative motor neuron disease. The aetiology of ALS remains an enigma which hinders the design of an effective treatment to prevent, postpone, or reverse the pathophysiological changes occurring during the aggressive progression of this disease. During the last decade, basic research within the innate immune sy...
Source: Molecular Immunology - Category: Allergy & Immunology Source Type: research
Ebel et al. evaluated the association between attention-deficit/hyperactivity disorder (ADHD) and amyotrophic lateral sclerosis (ALS) [1]. Sociodemographic factors and physical activities were also considered in the analysis. The authors cited a paper, presenting the hypothesis that there was a pathophysiological link between ADHD and ALS [2], however ALS patients reported a lower prevalence of childhood ADHD and there was no evidence that ADHD had been more common in ALS patients. I have 2 concerns about this study.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research
(MacDougall Biomedical Communications, Inc.) Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neurodegenerative therapeutics, announced today that it has been awarded $3.4 million from the National Institute of Neurological Disorders and Stroke (NINDS) in a competing grant to advance novel therapeutic drug candidates towards the clinic for treating patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Xueping Chen, Qian-Qian Wei, Yongping Chen, Bei Cao, RuWei Ou, Yanbing Hou, Xiaoqin Yuan, Lingyu Zhang, Hui Liu, Huifang Shang
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Publication date: Available online 18 June 2018 Source:Molecular and Cellular Neuroscience Author(s): Rachit Bakshi, Yuehang Xu, Kaly A. Mueller, Xiqun Chen, Eric Granucci, Sabrina Paganoni, Ghazaleh Sadri-Vakili, Michael A. Schwarzschild Dominant mutations in an antioxidant enzyme superoxide dismutase-1 (SOD1) cause amyotrophic lateral sclerosis (ALS), an adult-onset neurodegenerative disease characterized by loss of motor neurons. Oxidative stress has also been linked to many of the neurodegenerative diseases and is likely a central mechanism of motor neuron death in ALS. Astrocytes derived from mutant SOD1 G93A mouse m...
Source: Molecular and Cellular Neuroscience - Category: Neuroscience Source Type: research
More News: ALS | Clinical Trials | Pharmaceuticals